Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma

Table 1 Patient characteristics

Patient No.	Age (y) /Sex	Diagnosis	Prior Treatment					CAR-T Cells Dose and Routes
Patient No.	Age (y) /Sex	Diagnosis	Surgery	Radiation + TMZ	IDH1/2	MGMT	GD2 Intensity	CAR-T Cells Dose and Routes
01	63/F	GBM	Yes,×2	TMZ, No Radiation	WT	UM	4.0+	i.v. 1.3 × 10⁸ i.c. 5 × 10⁶
02	4/M	GBM	Yes,×2	Radiation, No TMZ	WT	UM	3.0+	i.v. 6.4 × 10⁷ i.c. 2.6 × 10⁶
03	6/F	GBM	Yes	Yes	WT	UM	2.0+	i.v. 4.6 × 10⁷
04	38/F	GBM	Yes	Yes	WT	UM	2.5+	i.v. 1.4 × 10⁸
05	29/M	GBM	Yes,×2	Yes	WT	ML	2.0+	i.v. 1.6 × 10⁸ i.c. 6.4 × 10⁶
06	3/M	GBM	Yes	Radiation, No TMZ	WT	UM	3.5+	i.v. 3.8 × 10⁷
07	5/F	GBM	Yes	Radiation, No TMZ	WT	UM	1.5+	i.v. 3 × 10⁷
08	31/M	GBM	Yes	Yes	WT	UM	3.5+	i.v. 2.1 × 10⁸

TMZ Temozolomide, WT Wildtype, UM Unmethylated, ML Methylated, i.v. Intravenous, i.c. Intracavitary

ISSN: 1476-4598